Biodesix (BDSX) UBS Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
UBS Global Healthcare Conference summary
10 Nov, 2026Nodify opportunity and Q3 performance
U.S. annual incidental lung nodule estimates are now 5M–6M; Nodify CDT flags likely malignancy, while XL2 identifies likely benign nodules.
Q3 diagnostic testing revenue was $23M, up 16% YoY; 19,400 tests were performed, up 24%, with FY revenue still expected to exceed $100M.
Q3 performance was affected by lower sales capacity and greater-than-expected primary-care seasonality; October brought the strongest new-physician acquisition month and improving existing-customer orders.
Primary care represents 15% of patient volume and about 50% of the market; its decisions focus on surveillance versus specialist referral, unlike pulmonologists’ procedure decisions.
Adding CDT for 4–8 mm nodules can lower average ASP because it is lower priced than XL2, while supporting earlier cancer detection and increased ordering of both tests; gross margin remained above 80% for six consecutive quarters.
Commercial execution and care pathways
Q3 average sales headcount was 101; plans were to reach ~110 and target ~115 by year-end, hiring 6–8 reps per quarter to match recruiting and training capacity.
Reps historically begin covering their costs within a quarter and typically reach stride in 6–9 months; some continue growing after several years in the field.
CHEST introduced a structured framework for nodule-management programs, identifying biomarkers as a key component; distribution to members and implementation work are underway, including two West Coast health systems.
Formal guideline updates were rumored for Q1–Q2 2027; broader use of automated patient identification, algorithmic ordering, blood-draw access and electronic integrations could reduce reliance on high-touch sales and lift orders per customer.
Health-system economics center on finding missed cancers and avoiding unnecessary interventions; health-economic evidence has supported pricing and Medicare rates, with alternative payer models under discussion.
Digital diagnostics and data strategy
A radiomics-based lung nodule assessment developed with Vanderbilt is targeted for commercialization in 2028 and is intended to complement blood-based Nodify tests with high-specificity imaging signals.
The STRATIFY study, announced at CHEST, will assess clinical utility of Nodify CDT and XL2 and validate a radiomic classifier alongside the blood test; study findings are expected to inform the optimal workflow and patient populations.
First digital-platform data were expected at RSNA within weeks, followed shortly thereafter by an initial publication with test performance data.
STRATIFY will combine blood samples and CT scans; the resulting multimodal dataset and Diagnostic Cortex machine-learning platform could support further lung diagnostics and potential biopharma collaborations.
Latest events from Biodesix
- Testing volumes rose 24%, but execution and project timing tempered growth.BDSX
Q3 2026 - Sales and clinical momentum support growth, with profitability and pipeline progress in focus.BDSX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 34% to $26.9M, gross margin at 82%, and net loss improved by 37%.BDSX
Q2 2026 - Strong growth, digital expansion, and clinical innovation set the stage for a transformative 2025.BDSX
45th Annual William Blair Growth Stock Conference - Revenue and clinical adoption surge as targeted lung nodule diagnostics drive growth.BDSX
46th Annual William Blair Growth Stock Conference - Registering 375,000 shares for resale by a lender, with proceeds from warrant exercises for working capital.BDSX
Registration filing - Rapidly growing lung diagnostics innovator with strong financials and broad clinical impact.BDSX
Corporate presentation - Q1 2026 revenue rose 42% to $25.6M, with improved margins and raised full-year guidance.BDSX
Q1 2026 - Q1 2025 revenue up 21%, net loss improved 18%, and 2025 guidance set at $80–85 million.BDSX
Q1 2025